Research Letter
January 2016

Preexposure Prophylaxis Awareness and Use in a Population-Based Sample of Young Black Men Who Have Sex With Men

Author Affiliations
  • 1Department of Medicine, University of Chicago, Chicago, Illinois
  • 2NORC at the University of Chicago, Chicago, Illinois
  • 3Department of Public Health Sciences, University of Chicago, Chicago, Illinois
  • 4School of Social Service Administration, University of Chicago, Chicago, Illinois

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2016;176(1):136-138. doi:10.1001/jamainternmed.2015.6536

In the United States, reducing new human immunodeficiency virus (HIV) infections will require a determined focus on primary HIV prevention among young black men who have sex with men (YBMSM), the only group in the United States where HIV incidence has increased over the past decade.1 Through 2011, effective clinic-based HIV prevention interventions that target YBMSM have been virtually nonexistent.2 In 2012, the US Food and Drug Administration approved a preexposure prophylaxis (PrEP) consisting of daily oral tenofovir disoproxil fumarate and emtricitabine. This PrEP has an estimated effectiveness of over 90%3 and, therefore, an HIV prevention effect potential for several domestic HIV epicenters.4

First Page Preview View Large
First page PDF preview
First page PDF preview